Matarin Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Matarin Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-13,525	Closed	-$834K	–	202
2019 Q4	$834K	Sell	13,525 -14,107	-51%	-$934K	0.08%	194
2019 Q3	$2.01M	Sell	27,632 -112,151	-80%	-$8.39M	0.15%	170
2019 Q2	$11.5M	Buy	139,783 +4,384	+3%	+$312K	0.82%	42
2019 Q1	$9.55M	Buy	135,399 +12,760	+10%	+$751K	0.69%	59
2018 Q4	$5.52M	Buy	122,639 +37,667	+44%	+$1.97M	0.45%	78
2018 Q3	$4.8M	Buy	84,972 +11,806	+16%	+$722K	0.31%	109
2018 Q2	$4.89M	Buy	73,166 +36,361	+99%	+$2.27M	0.35%	100
2018 Q1	$2.14M	Buy	36,805 +23,540	+177%	+$1.49M	0.16%	169
2017 Q4	$855K	Buy	13,265 +2,532	+24%	+$158K	0.07%	214
2017 Q3	$563K	Hold	10,733	–	–	0.05%	232
2017 Q2	$502K	Sell	10,733 -1,350	-11%	-$65.1K	0.05%	221
2017 Q1	$598K	Buy	+12,083	New	+$678K	0.06%	216

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ICOM

Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Matarin Capital Management's ANIP Position: Q1 2020 in Review

Matarin Capital Management sold out of ANI Pharmaceuticals (ANIP) in Q1 2020, closing a stake of 13,525 shares — an estimated $834K sold.

Matarin Capital Management first reported a position in ANIP in Q1 2017 and held it in 12 quarters. The position peaked at $11.5M in Q2 2019. 140 funds tracked by Wall St. Rank hold ANIP as of Q1 2020.

Matarin Capital Management reported no remaining ANI Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Matarin Capital Management sold 13,525 ANI Pharmaceuticals shares in Q1 2020, an estimated $834K.
Matarin Capital Management first reported a position in ANI Pharmaceuticals in Q1 2017 and held it in 12 quarters.
Matarin Capital Management's ANI Pharmaceuticals position peaked at $11.5M in Q2 2019.
140 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2020.

Based on Matarin Capital Management's 13F filing for Q1 2020, filed 27 Apr 2020.